FindTrial
Sign In

52 WEEKS STUDY, WITH ACTIVE AND CONTROLLED COMPARATOR WITH PLACEBO, PARALLEL GROUPS, DOUBLE BLIND, RANDOMIZED TO ASSESS THE SAFETY AND EFFECTIVENESS OF THE DAILY DOSE OF 25 AND 50 MG OF MK-966 IN PATIENTS WITH Rheumatoid ARTHRITIS (PART I)

52 WEEKS STUDY, WITH ACTIVE AND CONTROLLED COMPARATOR WITH PLACEBO, PARALLEL GROUPS, DOUBLE BLIND, RANDOMIZED TO ASSESS THE SAFETY AND EFFECTIVENESS OF THE DAILY DOSE OF 25 AND 50 MG OF MK-966 IN PATIENTS WITH Rheumatoid ARTHRITIS (PART I)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-052-99
Enrollment
Unknown
Registered
1999-05-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

NA Type of group

Sponsors

MERCK SHARP & DOHME PERÚ S.R.L.,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: NA

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Outcome name:NA Measure:NA Timepoints:NA—

Secondary

MeasureTime frame
Outcome name:NA Measure:NA Timepoints:NA—

Contacts

Public ContactStela López

MERCK SHARP & DOHME PERÚ S.R.L

stela_lopez@merck.com4115935

Outcome results

None listed

Source: REPEC (via WHO ICTRP)